Mesoblast files applications with US FDA for HLHS therapy
The company has filed the applications based on Revascor’s data from a randomised, blinded, controlled prospective study carried out at a single centre in the US involving 19
A therapy platform developed by T3 Pharma using engineered Yersinia enterocolitica bacteria, delivers immune-modulating proteins to cancer cells and tumour micro-environments, sparing healthy tissues. The bacteria can be